$0.53
-0.01 (-1.16%)
Open$0.53
Previous Close$0.54
Day High$0.54
Day Low$0.53
52W High$1.45
52W Low$0.48
Volume—
Avg Volume22.0K
Market Cap2.45M
P/E Ratio—
EPS$-5.61
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+869.6% upside
Current
$0.53
$0.53
Target
$5.14
$5.14
$3.59
$5.14 avg
$6.80
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 484.7K | 468.9K | 455.7K |
| Net Income | -93,000 | -114,838 | -98,507 |
| Profit Margin | -19.2% | -24.5% | -21.6% |
| EBITDA | -101,936 | -104,145 | -94,610 |
| Free Cash Flow | -84,967 | -104,034 | -103,597 |
| Rev Growth | +6.2% | -0.5% | +16.3% |
| Debt/Equity | 0.77 | 0.85 | 0.69 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $250.82 | +0.83% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $417.84 | +0.40% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $138.14 | +1.67% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $516.44 | -1.77% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $805.97 | +1.00% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $227.12 | +1.42% | 35.2 | 28.41B |